Cogent Biosciences, Inc.
COGT
Rankning i aktier
#3254
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted... Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Aktiekurs
$31.37
Senast synkroniserad: 2026-10-20
Marknadsvärde
$5.44B
Förändring (1 dag)
4.54%
Förändring (1 år)
97.81%
Land
US
Handel Cogent Biosciences, Inc. (COGT)
Kategori
Healthcare
Historik för aktiesplit för Cogent Biosciences, Inc. (COGT)
Aktien Cogent Biosciences, Inc. (symbol: COGT) har genomgått totalt 1 aktiesplitar.
Den senaste spliten skedde den Nov 09, 2020.
En COGT-aktie köpt före Nov 09, 2020 motsvarar nu 0.25 COGT-aktier.
Den senaste spliten skedde den Nov 09, 2020.
En COGT-aktie köpt före Nov 09, 2020 motsvarar nu 0.25 COGT-aktier.
Lista över aktiesplitar
| År | Split | Multipel | Kumulativ multipel |
|---|---|---|---|
| 2020-11-09 | 1:4 | x0.25 | x0.25 |
Aktiesplitar för liknande företag eller konkurrenter
| Företag | Antal aktiesplitar | Kumulativ multipel | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
